N/A N=194 Effectiveness of Fluoroscopy-guided MLD for Treatment of BCRL
Breast Neoplasm · Lymphedema
Primary: Lymphoedema Volume at the Level of the Arm/ Hand — 1.228; 1.249; 1.218; 1.175 Inter-limb ratio
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=121 The Role of Biofeedback in Improving Continence After Anterior Resection
Rectal Neoplasms · Fecal Incontinence · Aged
Primary: Cleveland Clinic Incontinence (CCI) Score — 4.2; 3.7; 1.2; -0.7 score on a scale — p=0.54
N/A N=274 Cognitive-Behavioral Conjoint Therapy (CBCT) Project
Post Traumatic Stress Disorder
Primary: Clinician Administered PTSD Scale (CAPS) — 38.456522; 37.239130; 36.933333 score on a scale
N/A N=541 Cesarean Section Via Enhanced Recovery
Cesarean Section
Primary: Opioid Consumption — 60.34; 104.33 oral morphine equivalents (mg) — p=< 0.001
Phase 3 N=2,849 A Study of LY3819253 (LY-CoV555) and LY3832479 (LY-CoV016) in Participants With Mild to Moderate COVID-19 Illness
COVID-19
Primary: Phase 3: Percentage of Participants Who Experience COVID-Related Hospitalization or Death From Any Cause in 2800 mg Bamlanivumab/2800 mg Etesevimab, 700 mg…
Early Phase 1 N=7 Effect of Heat on Rivastigmine TDS Products
Bioavailability
Primary: Total Area Under the Curve (AUC) 0-12 Hours — 19.99; 19.22; 19.22; 16.57 ng*h/mL
Phase 1 N=28 Evaluating the Safety and Pharmacokinetics of VRC07-523LS in the Sera and Mucosae of Healthy, HIV-Uninfected Adult Participants
HIV Infections
Primary: Number of Participants Reporting Local Reactogenicity Signs and Symptoms — 5; 10; 6; 3 Participants
Phase 2 N=56 IV Iron Replacement for Iron Deficiency in Idiopathic Pulmonary Arterial Hypertension (IPAH) Patients
Pulmonary Arterial Hypertension · Iron Deficiency
Primary: Change in Exercise Capacity - Endurance — 315.44; 302.89 Seconds — p=0.6039
Phase 2 N=83 Clinical Trial to Evaluate CERC-002 in Adults With COVID-19 Pneumonia and Acute Lung Injury
COVID-19 Pneumonia · Acute Lung Injury · ARDS
Primary: Number of Subjects Alive and Free of Respiratory Failure — 26; 20 Participants — p=0.0440
N/A N=68 ACT1ON Phase 2 (SMART Pilot) and Phase 3 (Efficacy Trial Development)
Diabetes Mellitus, Type 1 · Overweight and Obesity
Primary: Change in Weight - Randomization 1 — -1.6; -1.8; -1.5 kilograms — p=0.98
N/A N=16 Feasibility Study for Heparin-free Hemodialysis With the Dialyzer With Endexo™
Chronic Kidney Diseases · Patient Requiring Heparin Free Dialysis Treatments
Primary: The Primary Endpoint is the Number and Percent (%) of Successful Heparin-free HD Sessions for Each Subject in Each Circuit. — 2.4; 2.9 number of successful HD sessions
Phase 2 N=392 Phase 2 Study of TD-9855 to Treat Fibromyalgia
Fibromyalgia
Primary: Percentage Change in Pain Score Based on the Mean of the Last 7 Daily Pain Numeric Rating Scale (NRS) Scores From the Daily Pain Diaries — -0.9; -1.2; -1.4 percentage…
Phase 1 N=206 Safety and Immunogenicity of the Bris10 M2SR and Sing2016 M2SR H3N2 Monovalent Influenza Vaccines
Influenza A
Primary: Number of Participants With Local and Systemic Adverse Events (AEs) Through 29 Days Post-vaccination With Bris10 M2SR and Cumulatively Through Day 209 — 28; 24…
N/A N=30 Assessment of Cognitive Function After Surgery in Two Types of Anesthesia in Patients Operated for Breast Cancer
Patients With Breast Cancer and Breast Surgery Requiring
Primary: Presence of Cognitive Impairment — 29.5; 29 score on a scale
Phase 1 N=14 Drug-drug Interaction Study of Gepotidacin
Infections, Bacterial
Primary: Cohort 1: Maximum Observed Concentration (Cmax) of Gepotidacin in Plasma — 4.817; 4.548 Micrograms per milliliter